Mesoblast (MSB) Stock Price, News & Analysis

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 10.19 million shs
• Average Volume: N/A
• Market Capitalization: A$2.32 billion
• P/E Ratio: N/A
• Dividend Yield: 2.58%
• Price Target: N/A
• Consensus Rating: N/A

MSB Stock Analysis - Frequently Asked Questions

How were Mesoblast's earnings last quarter?

Mesoblast Limited (ASX:MSB) announced its earnings results on Thursday, February, 21st. The company reported ($0.09) earnings per share (EPS) for the quarter. Mesoblast had a negative net margin of 1,490.27% and a negative trailing twelve-month return on equity of 17.79%.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Mesoblast (MESO), Fortescue (FMG), MicroStrategy (MSTR), Aus Tin Mining (ANW), OceanaGold (OGC), Piedmont Lithium (PLL) and Alliance Resource Partners (ARLP).

Company Calendar

• Last Earnings: 2/21/2019
• Today: 7/06/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: ASX:MSB
• CIK: N/A
• Web: www.mesoblast.com
• Phone: +61-3-96396036
• Fax: N/A
• Employees: 83
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 9.56
• Net Income: -A$87.96 million
• Net Margins: -1,490.27%
• Pretax Margin: N/A
• Return on Equity: -17.79%
• Return on Assets: -5.41%

Debt

• Debt-to-Equity Ratio: 24.76
• Current Ratio: 1.18
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: A$5.90 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 30.00
• Book Value: A$0.43 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,140,000,000
• Free Float: N/A
• Market Cap: A$2.32 billion
• Optionable: Not Optionable
• Beta: 2.38